Login

Cart

Your cart is empty

Article: Hhemp.co Expands its Cannabinoid Lineup With CBGa and CBDa Accelerated by COVID-19 Study Findings

PrevNext
Hhemp.co Expands its Cannabinoid Lineup With CBGa and CBDa Accelerated by COVID-19 Study Findings
cbd

Hhemp.co Expands its Cannabinoid Lineup With CBGa and CBDa Accelerated by COVID-19 Study Findings

Hhemp.co, the leading CBD:CBG product manufacturing and distribution company, is elevating its world-class line of products by introducing cannabinoids CBGa and CBDa.

Please click here to read the full article 

Read more

Recent Findings in COVID-19 Studies Accelerate Hhemp.co’s Plan to Launch New CBDa and CBGa Product Line
Alternative Medicine

Recent Findings in COVID-19 Studies Accelerate Hhemp.co’s Plan to Launch New CBDa and CBGa Product Line

HAYWARD, CA, UNITED STATES, February 8, 2022 /EINPresswire.com/ -- Premium hemp brand, Hhemp.co (“Hhemp.co” or “The Company”) is proud to announce its role in helping facilitate extraction for the ...

Read more
Hhempco at Kansas City Expo

Hhemp.co Attends Major Cannabis Expo In Kansas City

At Major Cannabis Expo, there was a wide array of businesses including vendors for glass, green, and gummies. Dispensaries and extract makers that are both out of state and locally-owned were repre...

Read more

Products listed contains a total delta-9 tetrahydrocannabinol concentration that does not exceed 0.30% on a dry-weight basis. The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease. None of the products contain any percentage of nictoine or tobacco. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product.